Fate Therapeutics Inc FATE.OQ FATE.O is expected to show a fall in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
The San Diego California-based company is expected to report a 40.7% decrease in revenue to $1.142 million from $1.93 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
LSEG's mean analyst estimate for Fate Therapeutics Inc is for a loss of 38 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 3.6% in the last three months.
Wall Street's median 12-month price target for Fate Therapeutics Inc is $5.00, above its last closing price of $1.17.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.43 | -0.43 | -0.44 | Missed | -1.7 |
Sep. 30 2024 | -0.41 | -0.43 | -0.40 | Beat | 7.5 |
Jun. 30 2024 | -0.47 | -0.48 | -0.33 | Beat | 30.6 |
Mar. 31 2024 | -0.48 | -0.49 | -0.47 | Beat | 3.8 |
Dec. 31 2023 | -0.53 | -0.52 | -0.45 | Beat | 13.9 |
Sep. 30 2023 | -0.56 | -0.57 | -0.46 | Beat | 19.3 |
Jun. 30 2023 | -0.58 | -0.59 | -0.54 | Beat | 8.2 |
Mar. 31 2023 | -0.64 | -0.62 | -0.19 | Beat | 69.5 |
This summary was machine generated May 5 at 22:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。